Quarter
Charts

SOLID BIOSCIENCES INC.

SLDB

CIK 0001707502 · Quarterly mode · latest period FY2022 (Q4) (ending 2022-12-31) · sourced from SEC EDGAR

At a glance · FY2022 (Q4)

Revenue
$8M
↓-40.6% -$6Mvs FY2021 (Q4)
Gross Profit
$8M
↓-40.6% -$6Mvs FY2021 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
17/100
  • Profitability
    0ROIC -89.2% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 6.14 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.03x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -40.6% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$1M
investment in PP&E
Stock-based comp (TTM)
$17M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$233M
everything owned
Total liabilities
$53M
everything owed
Stockholders' equity
$180M
shareholder claim

Recent performance · 36 quarters

Revenue↓-40.6% -$6M
$8M
Net Income↓-39.9% -$13M
$-46M
Free Cash Flow↓-177.0% -$361K
$-565K

Drill down

SLDB Sankey

See SOLID BIOSCIENCES INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

SLDB Charts

36 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

SLDB Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics